Calithera Biosciences (NASDAQ:CALA) Research Coverage Started at StockNews.com
Calithera Biosciences (NASDAQ:CALA) Research Coverage Started at StockNews.com
Analysts at StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a report released on Monday. The firm set a "hold" rating on the biotechnology company's stock.
股票新聞網的分析師開始對股票的覆蓋 卡利瑟拉生物科學 (納斯達克:卡拉 — 獲得評級) 在星期一發布的報告中。該公司對生物技術公司的股票設定了「持有」評級。
Calithera Biosciences Trading Down 1.8 %
卡利瑟拉生物科學交易下跌 1.8%
Shares of CALA opened at $0.04 on Monday. The company has a market cap of $215,254.00, a PE ratio of 0.00 and a beta of 1.22. The stock has a 50-day moving average price of $0.17 and a 200-day moving average price of $1.68. Calithera Biosciences has a 12-month low of $0.04 and a 12-month high of $13.38.
卡拉股票週一以 0.04 美元開盤。該公司的市值為 215,254.00 美元，聚乙烯比率為 0.00，測試版為 1.22。該股票的 50 天移動平均價為 0.17 美元，200 天移動平均價為 1.68 美元。卡利瑟拉生物科學有一個 12 個月低點 0.04 美元和 12 個月高點 13.38 美元。
Insider Activity
內幕活動
In related news, Director Deepika Pakianathan sold 121,333 shares of the business's stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $0.39, for a total value of $47,319.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.60% of the company's stock.
在相關新聞中，董事 Deepika 巴基斯坦人在 1 月 27 日（星期五）發生的一項交易中出售了該業務股票的 121,333 股。該股票以 0.39 美元的平均價格出售，總價值為 47,319.87 美元。該交易已在向證券交易委員會提交的文件中披露，該文件可在以下位置獲得： 此超連結。企業內部人士擁有公司股票的 6.60％。
Hedge Funds Weigh In On Calithera Biosciences
對沖基金權衡卡利塞拉生物科學
A number of large investors have recently bought and sold shares of the stock. TSP Capital Management Group LLC grew its stake in Calithera Biosciences by 18.0% in the third quarter. TSP Capital Management Group LLC now owns 62,900 shares of the biotechnology company's stock worth $185,000 after purchasing an additional 9,605 shares during the period. Renaissance Technologies LLC grew its stake in Calithera Biosciences by 13.8% in the third quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company's stock worth $337,000 after purchasing an additional 13,855 shares during the period. Vanguard Group Inc. grew its stake in Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after purchasing an additional 26,800 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 72,865 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Calithera Biosciences in the first quarter worth $404,000. 33.73% of the stock is owned by hedge funds and other institutional investors.
一些大型投資者最近買賣了該股票的股票。TSP 資本管理集團有限責任公司在第三季度增長了 18.0% 在卡利塞拉生物科學的股份.TSP 資本管理集團有限責任公司現在擁有該生物技術公司股票的 62,900 股價值 $185,000 在此期間額外購買 9,605 股後。文藝復興時期技術有限責任公司在第三季度增長了 13.8% 在卡利塞拉生物科學的股份.文藝復興技術有限責任公司現在擁有該生物技術公司股票的 114,555 股價值 337,000 美元後，在此期間額外購買 13,855 股股票。先鋒集團公司在第三季度增長了 23.4％ 在卡利塞拉生物科學的股份。領航集團股份有限公司現在擁有該生物科技公司股票的 141,217 股股份，價值 415,000 美元。高盛集團公司在第一季度將其在卡利塞拉生物科學的持有量提高了 143.2％。在上一季度額外收購 72,865 股後，高盛集團公司現在擁有該生物技術公司股票的 123,739 股，價值 50,000 美元。最後，阿麗斯卡投資集團股份有限公司在第一季度收購了價值 404,000 美元的卡利瑟拉生物科學的新股份。33.73％ 的股票由對沖基金和其他機構投資者擁有。
About Calithera Biosciences
關於卡利瑟拉生物科學
(Get Rating)
(取得評分)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Calithera Biosciences, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對腫瘤和抗癌免疫細胞中新穎和關鍵代謝途徑的小分子藥物。它提供了程序，如管道, 谷氨酰胺酶抑制劑, 和精氨酸酶抑制劑.
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 5 Best Dividend Capture Stocks
- 獲取有關卡利瑟拉生物科學研究報告的免費副本
- 市場節拍週的回顧 — 3 月 20 日 — 3/24
- 股息王原廠配件公司升級的利潤指導
- 底部是在埃森哲
- 11 股 2023 年最佳非必要消費品股票
- 5 個最佳股息捕捉股票
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收卡利塞拉生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收有關 Calithera 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。